Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Prevention of macrovascular disease in patients with short-duration type 2 diabetes by multifactorial target control: an 8-year prospective study.

Wu WX, Ren M, Cheng H, Li Y, Qi YQ, Yang C, Yan L.

Endocrine. 2014 Nov;47(2):485-92. doi: 10.1007/s12020-013-0158-x. Epub 2014 Jan 23.

PMID:
24452874
2.

Primary prevention of macroangiopathy in patients with short-duration type 2 diabetes by intensified multifactorial intervention: seven-year follow-up of diabetes complications in Chinese.

Yang Y, Yao JJ, Du JL, Bai R, Sun LP, Sun GH, Song GR, Cao SM, Shi CH, Ba Y, Xing Q, Zhang XY.

Diabetes Care. 2013 Apr;36(4):978-84. doi: 10.2337/dc12-0227. Epub 2012 Dec 10.

4.

Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.

Tandon N, Ali MK, Narayan KM.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000. Review.

PMID:
22217193
6.

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.

N Engl J Med. 2003 Jan 30;348(5):383-93.

8.
9.

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.

[No authors listed]

Diabetes. 1995 Nov;44(11):1249-58. Erratum in: Diabetes 1996 Nov;45(11):1655.

PMID:
7589820
10.

Multifactorial aspects of the treatment of the type II diabetic patient.

Colwell JA.

Metabolism. 1997 Dec;46(12 Suppl 1):1-4. Review.

PMID:
9439550
11.

Effects of five-year intensive multifactorial intervention on the serum amyloid A and macroangiopathy in patients with short-duration type 2 diabetes mellitus.

Du JL, Liu JF, Men LL, Yao JJ, Sun LP, Sun GH, Song GR, Yang Y, Bai R, Xing Q, Li CC, Sun CK.

Chin Med J (Engl). 2009 Nov 5;122(21):2560-6.

PMID:
19951570
12.

Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.

Seidu S, Achana FA, Gray LJ, Davies MJ, Khunti K.

Diabet Med. 2016 Mar;33(3):280-9. doi: 10.1111/dme.12885. Epub 2015 Sep 8. Review.

PMID:
26282461
13.

Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.

Dailey G.

Clin Ther. 2011 Jun;33(6):665-78. doi: 10.1016/j.clinthera.2011.04.025. Review.

PMID:
21704233
15.

Association of impaired glucose homeostasis with preclinical carotid atherosclerosis in women: Impact of the new American Diabetes Association criteria.

De Michele M, Panico S, Celentano E, Covetti G, Intrieri M, Zarrilli F, Sacchetti L, Tang R, Bond MG, Rubba P.

Metabolism. 2002 Jan;51(1):52-6.

PMID:
11782872
17.

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.

Rodríguez A, Reviriego J, Karamanos V, del Cañizo FJ, Vlachogiannis N, Drossinos V; ECLA Study Group.

Cardiovasc Diabetol. 2011 Feb 11;10:18. doi: 10.1186/1475-2840-10-18.

18.

Basal insulin and cardiovascular and other outcomes in dysglycemia.

ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.

19.
20.

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.

Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators.

JAMA. 2008 Nov 12;300(18):2134-41. doi: 10.1001/jama.2008.623. Epub 2008 Nov 9. Erratum in: JAMA. 2009 May 13;301(18):1882. JAMA. 2012 Nov 14;308(18):1861.

PMID:
18997198

Supplemental Content

Support Center